Abstract: Provided herein are TLR7/8 agonists to enhance immune responses or for use as adjuvants in fentanyl vaccines in opioid-using individuals.

Abstract: This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

Abstract: This disclosure describes a fentanyl hapten, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten and the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten and the fentanyl hapten-carrier conjugate. The fentanyl hapten-carrier conjugate may be used, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl and its analogues. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

Abstract: This disclosure describes opioid-specific monoclonal antibodies (mAb), methods of making those antibodies, and methods of using those antibodies. The methods include, for example, treating a subject with an opioid use disorder or neonatal opioid withdrawal syndrome or preventing and reversing opioid overdose in a subject. Additionally or alternatively, the antibodies may be used to detect opioids including, for example, in a screening, diagnostic, or forensic assay.

Abstract: A method generally includes co-administering to a subject a composition that includes an antigen and a cytokine signaling immunomodulator. The method can be for treating a subject for abuse of a drug, treating a subject for toxicity from drug abuse, treating a subject for infection by a pathogen, treating a subject for a non-communicable disease, or for increasing antibody production against the antigen. The antigen can be component of a vaccine. The cytokine-signaling immunomodulator is effective to improve the subject's immune response to the antigen compared to the subject's immune response to the antigen without the cytokine-signaling immunomodulator.

Abstract: The present invention relates to conjugates and vaccine compositions for treatment of opioid addiction, and methods of use of these conjugates and compositions.